Sulfamethoxazole + Trimethoprim Suspension manufacturers & suppliers

Sulfamethoxazole + Trimethoprim Suspension

Form: Suspension

Strength: 80 mg/400 mg per 5 mL, 160 mg/800 mg per 5 mL

Reference Brands: Bactrim(US)

Category: Antibiotics

Sulfamethoxazole + Trimethoprim suspension is approved in the EU and US for urinary tract, respiratory, and skin infections. In the EU, brands like Bactrim and Septra are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access for sulfamethoxazole + trimethoprim suspension, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details
Fosfomycin Oral Sachets Or Powder For Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details
Fosfomycin Iv

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more